A Pioneering
Portfolio.

Brexpiprazole TiP

Brexpiprazole is a dopamine D2 receptor partial agonist, and has been described as a serotonin–dopamine activity modulator.

Used for the treatment of schizophrenia and as an adjunctive treatment for depression, Brexpiprazole acts as an atypical antipsychotic, our transdermal product already has its API sourced, and formulation development has commenced.

Cariprazine TiP

Used to treat mental disorders such as bipolar and schizophrenia, Cariprazine acts as either an agonist or antagonist depending on the current concentration of central dopamine D2 and serotonin 5-HT1A neurotransmitters in the brain.

Our products offer 1-2 day dosages ranging from 1mg through 6mg.  Final formulation and skin permeation studies are complete for this product, and clinical studies are planned for mid/late 2021.

Dapagliflozin TiP

Used to control blood sugar in people with type 2 diabetes, Dapagliflozin is active sodium glucose cotransporter type 2 (SGLT-2) inhibitor; inhibiting SGLT2 activity modulates reabsorption of glucose in the kidney, resulting in excretion of glucose in the urine.

Final formulation and skin permeation studies are complete for this product, and clinical studies are planned for mid/late 2021.

Dasatinib TiP

As a synthetic small molecule-inhibitor of the SRC-family protein-tyrosine kinases, Dasatinib binds to and inhibits the growth-promoting activities of these kinases and is used as a treatment for leukemia.

Skin permeation studies have been completed, and clinical studies are planned for mid/late 2021.

Donepezil TiP

Often used to treat confusion (dementia) related to Alzheimer's disease, Donepezil is an enzyme blocker that works by restoring the balance of natural substances (neurotransmitters) in the brain.

The formulation is complete on the 5mg and 10mg 7 day TiP variant of Donepezil, technical documents have been written, draft IMPD is under review, and clinical studies are starting mid 2021.

Everolimus TiP

Everolimus is an antineoplastic chemotherapy drug that is also indicated for organ rejection in transplants. Everolimus binds to its protein receptor FKBP12, which directly interacts with mTORC1, inhibiting its downstream signaling. As a consequence, mRNAs that code for proteins implicated in the cell cycle and in the glycolysis process are impaired or altered, and tumor growth is inhibited.

Currently being developed in 1-3 day dosages ranging from 0.25mg through 3mg, our API’s are sourced and we are positioned to proceed with formulation discovery.

Fingolimod TiP

Fingolimod, used to treat multiple sclerosis, is a sphingosine 1-phosphate receptor modulator. The exact mechanism is unknown, but Fingolimod is thought to work by reducing the immune system's attack on the central nervous system by retaining certain white blood cells (lymphocytes) in the lymph nodes.

At Greene Street, we are developing dosages ranging from 0.25mg through 1mg. We have already sourced an API and are positioned to proceed with formulation discovery.

Lenalidomide TiP

An antiangiogenic treatment that reduces levels of VEGF, TNFa, and IL-6, Lenalidomide is used for the treatment multiple myeloma and myelodysplastic syndromes and is generally taken together with dexamethasone.

Our 5 and 10mg 1-3 day Lenalidomide TiP version skin permeation studies have been completed, and clinical studies are planned for mid/late 2021.

Levothyroxine TiP

Levothyroxine is a synthetically prepared levo-isomer of the thyroid hormone thyroxine (T4, a tetra-iodinated tyrosine derivative) that acts as a replacement in deficiency syndromes such as hypothyroidism.

We are currently developing dosages ranging from 25mcg through 300mcg 1-5 day versions, and are in the process if identifying formulations and studying skin permeation.

Pitavastatin TiP

Our 1-3 day dosages, ranging from 1mg through 4mg, are ready to process with formulation discovery.

Primarily used to lower bad cholesterol and promote good cholesterol, by completely inhibiting HMG CoA reductase, the rate-determining enzyme in hepatic cholesterol synthesis. Pitavastatin increases the LDL-C receptors in the liver, thereby increasing the removal of LDL-C from the blood.

Pomalidomide TiP

Currently in the formulation discovery phase for Pomalidomide, we are developing 1-3 day dosages, ranging from 1mg through 4mg for this product.

Used to treat people with multiple myeloma who have previously been treated with at least two medicines, including a proteasome inhibitor and Lenalidomide, and whose disease became worse during treatment, Pomalidomide directly inhibits both angiogenesis and myeloma cell growth.

Tizanidine TiP

Tizanidine is a short-acting muscle relaxer that works by blocking nerve impulses (pain sensations) that are sent to the brain. It is primarily used to treat spasticity by temporarily relaxing muscle tone.

Currently in the post-animal PK testing phase, Greene Street Manufacturing are positioned to produce both 2 and 4 mg, 3 day transdermal dosages.

Tofacitinib TiP

Common side effects of Tofacitinib, used primarily to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis, include diarrhea, headache, and high blood pressure, with more serious side effects not limited to infections and pulmonary embolism. The 2 day patch developed by Greene Street currently will avoid the GI associated side effects.

Final formulation and skin permeation studies are complete for this product, and clinical studies are planned for mid/late 2021.